Hirudo tianjinensis Multimeric Hirudin
Multi-domain hirudin superfamily proteins from H. tianjinensis (Kalatehjari 2026) — two-or-more central globular domains per molecule.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Multi-domain hirudin superfamily proteins from H. tianjinensis (Kalatehjari 2026) — two-or-more central globular domains per molecule.
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
Multimeric hirudin's in vitro thrombin inhibition does NOT establish clinical efficacy. No FDA-approved multimeric hirudin derivative exists; clinical hirudin analogs (lepirudin, desirudin) are monomeric.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 15,000 Da
- Source species
- Hirudo tianjinensis
- Discovered
- 2026 · Kalatehjari P et al.
Biological Targets
- → thrombin (multivalent binding via multiple globular domains)
Key Citations
- Kalatehjari P et al. (2026), Parasitol Res · PMID 41653280
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.